Free Trial
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Gemini Therapeutics logo
$46.87 +1.75 (+3.88%)
As of 05/29/2025

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Key Stats

Today's Range
$44.96
$47.36
50-Day Range
$34.28
$52.79
52-Week Range
$1.16
$14.10
Volume
337,234 shs
Average Volume
189,291 shs
Market Capitalization
$2.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GMTX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

GMTX Stock Analysis - Frequently Asked Questions

Gemini Therapeutics' stock was trading at $63.40 at the start of the year. Since then, GMTX shares have decreased by 26.1% and is now trading at $46.87.
View the best growth stocks for 2025 here
.

Gemini Therapeutics, Inc. (NASDAQ:GMTX) issued its earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04.

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Video Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

Last Earnings
11/15/2021
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$71.87 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
16.22

Miscellaneous

Free Float
37,739,000
Market Cap
$2.03 billion
Optionable
Not Optionable
Beta
-0.12
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:GMTX) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners